Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Looking Into Abbott Laboratories's Recent Short Interest
Merck & Co Analyst Ratings